ArticleBiological psychiatry2026
G Protein Inactivation as a Mechanism for Addiction Treatment.
Article in Biological psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
backgroundThe endogenous dynorphin/kappa opioid receptor (KOR) system in the brain mediates the dysphoric effects of stress, and KOR antagonists may have therapeutic potential for the treatment of drug addiction, depression, and psychosis. One class of KOR antagonists, the long-acting norbinaltorphimine (norBNI)-like antagonists, have been suggested to act by causing KOR inactivation through a c-Jun-kinase mechanism rather than by competitive inhibition.
methodsIn this study, we screened for other opioid ligands that might produce norBNI-like KOR inactivation and found that nalfurafine (a G-biased KOR agonist) and nalmefene (a KOR partial agonist) also produced long-lasting KOR inactivation.
resultsNeither nalfurafine nor nalmefene is a completely selective KOR ligand, but KOR inactivation was observed at doses 10- to 100-fold lower than necessary for mu opioid receptor actions. KOR inactivation is sex dependent, and we show that nalfurafine causes peroxide production only during estrus (low-estrogen state) or after progesterone treatment of female mice. Because KOR inactivation recovers slowly, daily treatment with submaximal drug doses causes accumulating inhibition. Daily microdosing with nalfurafine or nalmefene blocked KORs responsible for antinociceptive effects, blocked KORs mediating stress-induced aversion, mitigated KOR-mediated dysphoria during acute and protracted withdrawal in opioid-dependent mice, and blocked KOR-induced prolactin secretion. In contrast, KORs mediating the diuretic and antipruritic effects were not regulated by JNK (c-Jun N-terminal kinase).
conclusionsBoth nalfurafine and nalmefene have long histories of safety and use in humans and could potentially be repurposed for the treatment of dynorphin-mediated stress disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.